Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Escient Pharmaceuticals Inc. maintains a patent portfolio currently facing 2 pending office actions. These actions are situated within the Biotechnology & Pharmaceuticals technology area, which involves specific examination standards. The prosecution is distributed across 2 distinct examiners and 2 distinct art units, reflecting a distribution of its intellectual property filings across different specialized groups.
WILLIS, DOUGLAS M is the busiest examiner associated with the portfolio. This examiner is currently managing 1 busiest examiner pending action. Given that there are 2 pending office actions in total across 2 distinct examiners, the workload is distributed among these individuals. This distribution suggests that no single examiner or art unit currently dominates the company's active legal challenges.
Practitioners should note that the presence of 2 distinct art units for only 2 pending actions indicates that Escient Pharmaceuticals Inc. is navigating multiple examination frameworks simultaneously. This variety requires tailored strategies for each specific art unit within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245700 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | JARRELL, NOBLE E | 73d overdue |
| 18497879 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | WILLIS, DOUGLAS M | 16d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18497879 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | WILLIS, DOUGLAS M | 16d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18497879 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | 16d | Pending | Oct 30, 2023 |
| 18245700 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | JARRELL, NOBLE E | 1699 | §102 | Final Rejection | 73d overdue | Pending | Mar 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial